Cyclic Lipodepsipeptides Targeting Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotic development strategies have been inadequate in addressing antibiotic-resistant Gram-negative bacteria, such as carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae, necessitating the discovery of novel antibacterial compounds.
Innovation Solution
Development of novel cyclic and non-cyclic peptides, specifically cyclic lipodepsipeptides, which are synthesized or isolated from natural sources, exhibiting potent antibacterial activity against Gram-negative and Gram-positive bacteria, including resistant strains, through peptide synthesis or recombinant DNA technology.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If rational drug design and synthesis against selected druggable targets are used, then novel classes of antibiotics can be developed, but success rate is low compared to natural products
Solution Approach 1:
The patent modifies the chemical parameters of natural product structures by introducing specific substitutions at defined positions (R1-R13 groups) to enhance antibacterial activity against resistant strains while maintaining the core cyclic lipodepsipeptide structure that ensures biological effectiveness
Solution Approach 2:
The invention combines elements of natural product chemistry (cyclic lipodepsipeptide core structure) with synthetic modifications (various R group substitutions) to create hybrid molecules that possess both the biological activity of natural products and the tunability of synthetic compounds
2Reliability
If cyclic lipodepsipeptides are developed to target Gram-negative bacteria, then antibacterial efficacy is improved, but compound complexity increases
Solution Approach 1:
The patent divides the molecular structure into distinct functional segments: a core cyclic lipodepsipeptide framework (positions 1-9) that provides biological activity, and variable substituent groups (R1-R13) that can be independently optimized, allowing systematic development of analogs with reduced complexity while maintaining efficacy
Solution Approach 2:
The invention applies specific substitutions at localized positions (R1-R13) rather than throughout the entire molecule, allowing targeted modification of properties such as lipophilicity, size, and aromaticity to improve Gram-negative bacterial targeting while keeping the rest of the structure simple and well-defined
Data Source
AI summary
The present invention relates to novel compounds, which presents a peptide structure and an unexpected antibacterial effect even against certain multiresistant bacteria. The compounds may be cyclic peptides, sometimes depsipeptides, or non-ring-closed peptides, as defined by Formula (I). Further, the invention relates to the medical use of the herein claimed compounds, a method for the production of the compounds as well as a method of treatment including the compounds. In addition, the invention relates to a pharmaceutical preparation comprising one or more of the herein described and claimed compounds combined with suitable carrier(s) and/or adjuvant(s). Finally, the invention is the use of one or more of the claimed compounds in a method for decolonization of a surface of Gram-positive and/or Gram-negative bacteria.